Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘castle’

Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma

Posted by fidest press agency su martedì, 31 dicembre 2019

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that results from a study designed to perform a systematic review of the literature and establish the level of evidence for the Company’s DecisionDx®-Melanoma gene expression profile test were published in the December 2019 issue of the American Journal of Clinical Dermatology. The results show that the DecisionDx-Melanoma test achieves a higher level of evidence than determined by major organizations that publish guidelines on melanoma management. DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors. In this independent study by Dubin, et al. titled, “Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma,” the researchers conducted a review of seven development and validation studies for the DecisionDx-Melanoma test. They then applied attributes of each study to the level of evidence criteria for the American Joint Committee on Cancer (AJCC), National Comprehensive Cancer Network (NCCN) and American Academy of Dermatology (AAD). The AJCC, NCCN and AAD are considered major authoritative organizations that many dermatologists rely upon to provide skin cancer guidelines, and each employs a unique ranking system to assign a level of evidence to the management of melanoma.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Castle Biosciences to Present at the 2018 Piper Jaffray Healthcare Conference

Posted by fidest press agency su venerdì, 23 novembre 2018

Castle Biosciences, Inc., a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced that Derek Maetzold, President and CEO, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28th, 2018 at 10:10 a.m. EST in New York City.Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about treatment and follow up care based on the individual molecular signature of the patient’s tumor. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq; and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq;, with programs in development for other underserved cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The new President Castello di Rivoli Museum

Posted by fidest press agency su lunedì, 23 novembre 2009

Museo D’arte Contemporanea Giovanni Minoli is the new President of the Board of Trustees of the Castello di Rivoli – the Museum is searching for a new Director The Board of Trustees of the Castello di Rivoli Museum of Contemporary Art announces that it has appointed Giovanni Minoli as new President of the Board. The Castello di Rivoli is one of Europe’s leading institutions for collecting and exhibiting contemporary art and was founded in 1984 on the premises of a Baroque castle near Turin, Piedmont. Born in Turin in 1945, since 2002 Minoli has been the Director of RAI Educational, the Italian public television dedicated to Education and the sharing of scientific and cultural knowledge through the broadcasting of programs, both produced by RAI Educational and acquired. RAI Educational has two channels of its own – RAI Edu 1 and RAI Storia – that broadcast 24 hours daily. The President of the museum announces as his first step in this new engagement with the museum, that the search for the new Director is currently underway. To succeed Ida Gianelli, whose term ended in late 2008, and Carolyn Christov-Bakargiev, who will leave the Museum at the end of 2009 to direct documenta 13, Kassel, the new Director will be appointed by the Board on the basis of written proposals and interviews with a shortlist of candidates, selected from a list of nominees. For this process, the Board and the President have formed a nominating committee, to which they have invited the former directors of the Museum, Rudi Fuchs and Ida Gianelli; the current interim acting director, Carolyn Christov-Bakargiev; the directors of three leading institutions for contemporary art in Turin – Francesco Bonami, Director of the Fondazione Sandretto Re Rebaudengo; Danilo Eccher, Director of the GAM Galleria Civica d’Arte Moderna e Contemporanea; and Beatrice Merz, Director of the Fondazione Merz; as well as five directors of leading international museum institutions – Neal Benezra, Director of SFMoMA The San Francisco Museum of Modern Art; Manuel Borja-Villel, Director of the MNCARS Museo Nacional Centro de Arte Reina Sofía, Madrid; Charles Esche, Director of the Van Abbemuseum, Eindhoven; Udo Kittelmann, Director of the Nationalgalerie in Berlin, including the Hamburger Bahnhof and the Neue Nationalgalerie; and Sir Nicholas Serota, Director of Tate, including Tate Britain, Tate Liverpool, Tate St Ives and Tate Modern.

Posted in Mostre - Spettacoli/Exhibitions – Theatre | Contrassegnato da tag: , , , | Leave a Comment »